SEC Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Sanofi to the U.S. Securities and Exchange Commission. The document details the company's holdings in equity securities as of the reporting period ending June 30, 2026. The filing lists specific positions in biotechnology and pharmaceutical companies, indicating Sanofi's investment strategy in the sector.
Key Financial Metrics and Holdings
The filing provides a snapshot of Sanofi's portfolio of equity investments. The table lists the issuer name, class of security, CUSIP, total value, share amount, and voting authority. Key holdings include:
- Inhibrx Biosciences, Inc.: 1,157,926 shares valued at $109,713,489.
- MeiraGTx Holdings plc: 12,197,737 shares valued at $164,791,427.
- Novavax: 6,880,481 shares valued at $64,814,131.
- Agomab Therapeutics NV: 2,783,096 shares valued at $36,124,586.
- Odyssey Therapeutics Inc.: 1,991,918 shares valued at $37,268,786.
The filing does not provide aggregate revenue, profit, cash flow, or debt metrics for Sanofi itself, as Form 13F is strictly a disclosure of securities holdings.
Material Changes and Voting Authority
The filing indicates that Sanofi holds Sole voting authority for all listed positions. There are no shared or none voting authority entries in this specific table. The document does not contain comparative data against a prior period to determine material changes in holdings volume or value.
Guidance, Risks, and Contingencies
As a standard Form 13F filing, this document does not contain management commentary, future guidance, risk factors, or contingency plans. It is a regulatory disclosure of current asset ownership.
Investor Verification Checklist
- Verify the total aggregate value of Sanofi's disclosed biotech portfolio against the sum of individual line items.
- Confirm the accuracy of the share counts and CUSIP numbers for the listed issuers (e.g., Inhibrx, MeiraGTx, Novavax).
- Check subsequent filings to track changes in these positions relative to the June 30, 2026, snapshot.
- Review the "Sole" voting authority designation to understand Sanofi's level of control or influence over these investees.